abbvie's nyse - Yahoo Search Results

Ads
related to: abbvie's nyse
AbbVie Inc. - AbbVie Inc. Leadership Team

abbvie.com
See What AbbVie Does To Make An Impact On Patients' Lives. See Our Mission & Principles. A Research-Driven Biopharmaceutical Company. See How AbbVie Go Beyond Treating Diseases.
Our Strategy · Ethics & Compliance · Supporting Workforce · About AbbVie
Investor Resources
Find Financial Reports, Stock Info

And More Resources For Investors.

Read AbbVie Stories
Read Stories About Our Science,

People, and More Today.

AbbVie News Center
See Our Achievements, Growth Story,

and More Today.

Our Science
See How We Impact Lives.

More Than Developing Medicines.
Explore Top Companies in QQQ - Rethink possible: Invesco QQQ

www.invesco.com
invesco.com has been visited by 100K+ users in the past month
Invest in some of today’s most innovative companies, all in one exchange-traded fund (ETF). Invesco QQQ: Not investing in the future? That’s madness

Search results

- Is AbbVie's Dividend Yield Safe?
  Motley Fool· 11 months ago
  AbbVie (NYSE: ABBV) is a leading pharmaceutical company that rewards its shareholders with a generous dividend policy. The company has a history of...
- AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48
  Simply Wall St. via Yahoo Finance· 1 year ago
  The board of AbbVie Inc. (NYSE:ABBV) has announced that it will be paying its dividend of $1.48 on...
- Do Humira Biosimilars Threaten AbbVie's Dividend?
  Motley Fool· 1 year ago
  Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current...
- AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's
  Simply Wall St. via Yahoo Finance· 2 years ago
  AbbVie Inc. (NYSE:ABBV) will increase its dividend from last year's comparable payment on the 15th...
- Is This the Start of a Nightmare for AbbVie Stock?
  Motley Fool· 1 year ago
  With a small army of Wall Street analysts predicting on average that AbbVie's (NYSE: ABBV) revenue will shrink in 2023 as well as in 2024, investors are...
- Is AbbVie a Buy?
  Motley Fool· 2 years ago
  Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its...
- Is AbbVie Stock a Buy Now?
  Motley Fool via Yahoo Finance· 3 months ago
  Pharmaceutical giant AbbVie (NYSE: ABBV) is undergoing significant changes. Last year, the company lost U.S. patent exclusivity for its biggest cash cow,...
- AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55
  Simply Wall St. via Yahoo Finance· 7 months ago
  AbbVie Inc.'s (NYSE:ABBV) dividend will be increasing from last year's payment of the same period to...
- AbbVie's Imbruvica Scores First Approval For Pediatric Patients After Bone Marrow Transplant
  Benzinga via Yahoo Finance· 2 years ago
  The FDA approved AbbVie Inc's (NYSE: ABBV) Imbruvica (ibrutinib) for pediatric patients one year and...
- Could This Drug News Lift AbbVie's Stock?
  Motley Fool· 1 year ago
  Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day...